Related Experiment Videos
Interferon-alpha plus ribavirin combination therapy for the treatment of chronic hepatitis C in interferon
F Hasan1, H Asker, M al Shamali
1Department of Medicine, Faculty of Medicine Kuwait University, PO Box 24923, Safat, Kuwait.
Background/Aims:
Only a small fraction of patients with chronic hepatitis C have a sustained biochemical or virologic response to a standard course of alpha-interferon therapy. Thus, alternative treatments are needed particularly for non-responders. The main objective of this study was to evaluate the efficacy of alpha-interferon in combination with ribavirin in patients who had not responded to a previous course of alpha-interferon.
Methodology:
In this prospective open trial, 26 patients who had not responded to a previous course of interferon monotherapy, were treated for 6 months with a combination of alpha-interferon 2b, 5 MU thrice weekly, plus ribavirin 1000 or 1200 mg daily. They were followed-up for at least 6 months after therapy.
Results:
At the end of treatment, 3 patients (12%) had normal aminotransferase levels and two (8%) tested negative for HCV-RNA in serum. After 6 months of follow-up, all patients had HCV viremia and only one (3.8%) was still in biochemical remission. One patient dropped out because of side effects and another was lost during follow-up.
Conclusions:
alpha-interferon-ribavirin combination is ineffective in treating patients who had had no response to interferon monotherapy.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Antiviral Nucleoside Inhibitors
Viral Hepatitis I: Introduction
Inhibitors Of Virion Release
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...